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Aim: To assess the potential of supervised machine-learning techniques to identify clinical
variables for predicting short-term and long-term glycated haemoglobin (HbA1c) response
after insulin treatment initiation in patients with type 2 diabetes mellitus (T2DM).
Materials and methods: We included patients with T2DM from the Groningen Initia-
tive to Analyse Type 2 diabetes Treatment (GIANTT) database who started insulin
treatment between 2007 and 2013 and had a minimum follow-up of 2 years. Short-
and long-term responses at 6 (±2) and 24 (±2) months after insulin initiation, respec-
tively, were assessed. Patients were defined as good responders if they had a decrease
in HbA1c ≥ 5 mmol/mol or reached the recommended level of HbA1c ≤ 53 mmol/mol.
Twenty-four baseline clinical variables were used for the analysis and an elastic net
regularization technique was used for variable selection. The performance of three tra-
ditional machine-learning algorithms was compared for the prediction of short- and
long-term responses and the area under the receiver-operating characteristic curve
(AUC) was used to assess the performance of the prediction models.
Results: The elastic net regularization-based generalized linear model, which included
baseline HbA1c and estimated glomerular filtration rate, correctly classified short-
and long-term HbA1c response after treatment initiation, with AUCs of 0.80 (95% CI
0.78–0.83) and 0.81 (95% CI 0.79–0.84), respectively, and outperformed the other
machine-learning algorithms. Using baseline HbA1c alone, an AUC = 0.71 (95% CI
0.65–0.73) and 0.72 (95% CI 0.66–0.75) was obtained for predicting short-term and
long-term response, respectively.
Conclusions: Machine-learning algorithm performed well in the prediction of an indi-
vidual's short-term and long-term HbA1c response using baseline clinical variables.
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1 | INTRODUCTION
When oral therapies fail to control blood glucose levels or cause
severe side effects in patients with type 2 diabetes mellitus (T2DM),
insulin therapy is recommended.1 Approximately 15% to 24% of
patients with T2DM receive insulin treatment.2-4 Large variability in
response to insulin treatment is seen, resulting partly from differences
in demographic, genetic, clinical and psychosocial characteristics.5-11
Notably, suboptimal blood glucose levels could lead to higher risks of
cardiovascular complications and mortality.12
In clinical settings, identification of variables that can predict a
patient's individual response to insulin could help tailor treatment.
Previous studies have established prediction models for glycated
haemoglobin (HbA1c) response to insulin using univariate and multi-
variate analysis of several demographic and clinical variables.6-9,13
Amongst others, age, body mass index (BMI) and baseline HbA1c
appeared to influence HbA1c response after insulin treatment initia-
tion. Prediction models based on such traditional regression analyses,
however, have limited utility for clinical decision-making because they
do not personalize the prediction to the individual. Similarly, studies
that identify clinical characteristics of patients that are associated with
distinct HbA1c trajectories in patients with T2DM over the course of
insulin treatment via unsupervised clustering algorithms cannot suffi-
ciently guide clinical decision-making.14-18 Such studies lead to incon-
sistent groupings of patients, suggesting that cluster analysis driven
by outcome patterns is not helpful in predicting HbA1c responses
using clinical variables at baseline. There is a need for a more individu-
alized approach to support clinical decision-making and to guide per-
sonalized treatment for patients with T2DM in need of additional
treatment.
Over the last few decades, machine-learning algorithms have been
actively used for developing clinical decision support systems.19,20
Machine-learning algorithms can automatically identify important clin-
ical variables to predict a clinical outcome at individual patient level. In
the present study, our primary aims were to assess the performance
of supervised machine-learning-based clinical decision support tools
to predict short- and long-term HbA1c response after insulin initiation
in patients with T2DM and to identify clinical variables that can influ-
ence a patient's HbA1c response. The proposed supervised learning
approach in this study provides a quantitative probability measure of
HbA1c response for an individual patient. Our secondary aim was to
identify and characterize subgroups of patients with different HbA1c
responses after insulin initiation using the predictions made for indi-
viduals by machine-learning algorithms.
2 | MATERIALS AND METHODS
2.1 | Data source
Data were collected from the Groningen Initiative to Analyse Type
2 diabetes Treatment (GIANTT) database (https://www.giantt.nl).21
This longitudinal database contains routinely collected data of
patients with T2DM extracted from the electronic medical records of
general practices in the northern Netherlands.22 The dynamic nature
of the database allows the inclusion of newly diagnosed patients or
patients with T2DM newly registered in a participating general prac-
tice, for example, after moving into the area. Patients were excluded
when they moved out of the area, were no longer treated in primary
care or died. The GIANTT database includes prescription data, medical
history, results of routine laboratory tests and physical examinations
from >50 000 patients diagnosed with T2DM. Medical history con-
tains diagnoses, as documented in the electronic medical records by
means of the International Classification of Primary Care or short text
descriptions that were manually coded. The GIANTT data collection
and mapping procedures have been validated,22 and used in more
than 40 previous studies.
2.2 | Population inclusion criteria
Details of patient inclusion and exclusion criteria were published in a
previous study using the same dataset.18 In short, for the present
study, patients were eligible for inclusion if all of the following criteria
applied: (a) they were prescribed insulin for the first time between
January 1, 2007 and December 31, 2013; (b) they had an HbA1c mea-
surement at insulin initiation and at 6- (±2) and 24- (±2) month follow-
up; (c) they had at least one HbA1c measurement within 365 days
preceding insulin initiation; and (d) they had at least one insulin pre-
scription within 365 days before each follow-up HbA1c measurement
to ensure no discontinuation in the follow-up period.
2.3 | 3 baseline clinical variables
We used a set of 24 baseline clinical variables previously identified as
possibly relevant and available in the GIANTT database.18 This
included continuous variables (age, HbA1c, total cholesterol, triglycer-
ides, HDL cholesterol, LDL cholesterol, systolic blood pressure [SBP],
albumin-to-creatinine ratio [ACR], estimated glomerular filtration rate
[eGFR], BMI) and categorical variables (sex, diabetes duration
[≥2 years], micro/macro-albuminuria, smoking status, metformin use,
sulphonylurea use, acarbose use, thiazolidine use, dipeptidyl
peptidase-4 [DPP-4] inhibitor use, repaglinide use, history of cardio-
vascular disease, peripheral vascular disease, malignancy, and psycho-
logical conditions). Full details on these variables have been described
elsewhere18 and are also provided in File S1.
2.4 | Patient outcome
The primary outcome measure for this study was decrease in HbA1c
level after insulin treatment initiation in the short term (6 ± 2 months)
and long term (24 ± 2 months). Patients were identified as good
responders if there was a reduction in HbA1c of at least 5 mmol/mol
compared to baseline or if they reached an HbA1c level of
≤53 mmol/mol. If the reduction was <5 mmol/mol or HbA1c failed to
reach the level of 53 mmol/mol, patients were defined as poor
responders. The HbA1c level of 53 mmol/mol was the lowest
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recommended target level for patients with T2DM in the Netherlands
at the time of the study.1
2.5 | Statistical analysis and cross-validation
2.5.1 | Missing data
First, missing variables (excluding HbA1c as this was used in defining
the outcome) in the raw baseline data were imputed using a multiple
imputation by chained equations algorithm23 (triglyceride: 3%; total
cholesterol: 3.7%; LDL cholesterol: 3.1%; SBP: 24%; ACR: 14%; eGFR:
1.43%; BMI: 29%). Using imputed clinical variables, we used an elastic
net regularization technique24 for important variable selection, and
trained machine-learning algorithms to predict the probability of
HbA1c response after insulin treatment initiation. It should be noted
that several variables were correlated; for example, “total cholesterol”
and “triglycerides, HDL cholesterol and LDL-cholesterol,” and “ACR”
and “micro−/macroalbuminuria.” The elastic net regularization
technique is ideal for this application where data consist of multiple
highly correlated variables. The elastic net regularization technique
will assign large weight to the variable that has more discriminative
ability to distinguish between two groups.
2.5.2 | HbA1c response prediction system
Figure 1 shows the architecture of the proposed HbA1c response pre-
diction system. We compared the performance of three commonly
used traditional machine-learning algorithms: (a) an elastic net
regularization-based generalized linear model,24 (b) a support vector
machine25 and (c) random forests26 to predict HbA1c responses. We
evaluated the prediction performance of the machine-learning models
using a leave-one-subject-out (LOSO) cross-validation technique, that
is, we divided the data into N folds. In each fold, we used data from
N-1 subjects for training the prediction model and the remaining
unseen left-out data for testing. In each fold, variables in the training
F IGURE 1 Architecture of the
proposed supervised machine
learning based HbA1c response
prediction system. LT, long-term;
MICE, multiple imputation by chained
equations; ST, short-term
F IGURE 2 Flow chart illustrating
patient inclusion and exclusion criteria
used in this study to select patients
for the final analysis. GIANTT,
Groningen initiative to analyse type
2 diabetes treatment; HbA1c, glycated
haemoglobin
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set were standardized (by subtracting the mean and dividing by the
standard deviation), and the testing set predictors were standardized
with respect to the mean and standard deviation of the training set
before using them for classification. Since the training set contained
an unequal number of sample points from the two groups (responder
and non-responder), this created a group imbalance problem which
could severely bias the performance of the model. For this reason, we
created a balanced training set (in every iteration) by selecting random
samples from each group corresponding to the length of the smallest
group (which varies during each iteration). We further divided this
LOSO cross-validation into inner and outer validation. Inner cross-
validation was performed on the training set to estimate optimal
model parameters and discriminant predictors using a feature selec-
tion method. Outer cross-validation was performed on the training
set to estimate model performance. Details are provided in the next
sections.
2.5.3 | Inner cross-validation for training the
classifier model
The elastic net regularization algorithm requires tuning of the so-called
hyperparameters, α = ridge coefficient, and λ = amount of regularization,
before testing on the testing set. While α controls the number of vari-
ables to be included in the analysis, λ adjusts the amount of coefficient
shrinkage (or variable weights). The weights (or relative importance) of
individual variables provided by elastic net regularization during training
were used for selecting important predictors (variable selection). In each
internal cross-validation loop, we optimized the number of predictors and
hyperparameters (using grid search) to be included in the final model. We
used fivefold cross-validation on the training set (ie, using 80% training
set) to obtain these parameters. The optimal set of predictors and param-
eters that provided maximum average area under the receiver-operating
characteristic curve (AUC) over the fivefold training set was used to train
the final prediction model on the whole training set.
TABLE 1 Groupwise comparison of baseline characteristics of patients
Clinical variables All Group 1 Group 2 Group 3 Group 4
Total number of patients, n (%) 1188 (100) 558 (47) 36 (3) 558 (47) 36 (3)
Agea, years 66.10 (12.1) 65.2(12.5) 56.1(10) 67.4(11.6) 69.6(11.1)
Women, % 639 (54) 290 (52) 18 (50) 309 (55.4) 22 (61.1)
DMD, n (%) 1026 (86.4) 460 (82.4) 32 (88.9) 501 (89.8) 33 (91.6)
HbA1ca, mmol/Mol 64.7 (16.4) 76.1 (17.2) 61.8 (0.9) 57.4 (2.1) 62.2 (1.6)
Total cholesterol*, mmol/L 4.4 (1.0) 4.4(1.0) 4.2 (1.3) 4.4 (1.1) 4.6 (1.2)
Triglycerides, mmol/L 1.9 (1.1) 1.9 (1.1) 1.6 (0.7) 1.9 (1.1) 2.1 (1.2)
HDL cholesterol, mmol/L 1.2 (0.3) 1.2 (0.3) 1.0 (0.3) 1.2 (0.3) 1.3 (0.4)
LDL cholesterol, mmol/L 2.4 (0.9) 2.5(0.9) 2.3(1.0) 2.4(1.0) 2.4(0.9)
SBPa, mmHg 142 (19.4) 141.6 (20.4) 134.5 (14.9) 141.1 (18.5) 153.3 (19.7)
ACR, μg/mg 5.3 (16.1) 4.2 (12.2) 3.2 (7.8) 6.8 (22.0) 3.6 (8.6)
eGFRa, mL/min/1.73 m2 73.4 (22.2) 76.6 (21.3) 92.4 (15.6) 69.5 (22.3) 63.3 (20.7)
BMI, kg/m2 30.6 (5.4) 30.8(5.4) 30.2(5.7) 30.1(5.2) 35.0(9.4)
Micro/macroalbuminuria, n (%) 248 (21) 117 (21) 5 (13.9) 112 (20.1) 9 (25)
Smoker, n (%)* 147 (12.4) 69 (12.4) 9 (25) 67 (12) 2 (5.6)
Metformin, n (%) 773 (65.1) 390 (69.9) 20 (55.6) 347 (62.2) 16 (44.4)
Sulphonylureas, n (%) 769 (64.7) 371 (66.5) 22 (61.1) 350 (62.7) 26 (72.2)
Acarbose, n (%) 3 (0.3) 1 (0.2) 0 (0) 2 (0.4) 0 (0)
Thiazolidines, n (%) 113 (9.5) 27 (4.8) 0 (0) 70 (12.5) 16 (44.4)
DPP-4 inhibitors, n (%) 57 (4.8) 34 (6.1) 2 (5.6) 21 (3.8) 0 (0)
Other GLDs, n (%) 3 (0.2) 2 (0.4) 0 (0) 0 (0) 1 (2.8)
CV morbidity, n (%) 279 (23.5) 122 (21.9) 3 (8.3) 149 (26.7) 5 (13.9)
Peripheral vascular morbidity, n (%) 161(13.5) 68 (12.2) 1 (2.8) 84 (15.1) 8 (22.2)
Malignancy, n (%) 117 (9.8) 46 (8.2) 3 (8.3) 66 (11.8) 2 (5.6)
Psychological conditions, n(%) 83 (7) 48 (8.6) 1 (2.8) 30 (5.4) 4 (11.1)
Note: Group 1, short-term and long-term responders; Group 2, short-term responders; Group 3, no change in response; Group 4, long-term responders.
Note: Values are reported as mean (±SD) unless stated otherwise.
Abbreviations: BMI, body mass index; CV, cardiovascular, albumin-creatinine ratio; DMD, diabetes mellitus duration (≥2 years); DPP-4, dipeptidyl
peptidase-4; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus.
aSignificant differences (P < .05).
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2.5.4 | Outer cross-validation for testing the
prediction model
The final trained prediction model with optimal parameters in the
internal cross-validation loop was used to obtain the probability of
good HbA1c response on the testing data. We then obtained the average
performance across N-folds to evaluate the model performance. Thus, by
training the prediction model using only the training set (inner cross-vali-
dation) and testing it on the independent testing set (outer cross-valida-
tion), the proposed method using LOSO cross-validation provides nearly
unbiased estimates on new testing data.27
Two separate prediction models were developed to predict short-
term and long-term HbA1c response for a given patient. The
predicted output by each model was converted to posterior probabili-
ties via logit transformation, resulting in two probability scores
assigned for each patient. To identify subgroups of patients predicted
by the model with different HbA1c responses after insulin initiation,
we stratified the entire population by the median probability output
of the short-term as well as the long-term model, resulting in four sub-
groups. Baseline characteristics were described for each subgroup and
ANOVA, followed by post hoc testing with the Tukey honest signifi-
cant difference test to assess differences in these characteristics
between the groups. The Kruskal–Wallis test was used for non-
normally distributed variables. All tests were two-sided with an α
value = .05. There was no a priori power analysis to guide sample size
in data collection.
2.6 | Performance metric
We used the AUC as the performance metric to evaluate the perfor-
mance of the proposed system. This metric provides an estimate of
how well the model can differentiate between two groups (good
responders vs poor responders). The higher the AUC, the better the
model performance: AUC = 1 indicated the best performance and
AUC = 0.5 corresponded to random performance. An AUC ≥0.8 was
considered good performance. We compared the AUC of different
models with a prediction model including only the baseline HbA1c. All
of the coding and analyses were performed using the MATLAB 2018a
scripting language (Natick, Massachusetts). All results are reported as
mean (±95% CI) unless stated otherwise. Bootstrapping with 1000
samples was used to estimate the 95% CI.
3 | RESULTS
In total, data from 1188 patients satisfying all inclusion and exclusion
criteria were used in this study (Figure 2). The majority of patients
(3341 patients) were excluded because their follow-up period was too
F IGURE 3 Heatmap illustrating the
of set of clinical variables selected
(in columns) by the elastic net
regularization techniques across different
leave one out iterations (in rows) for A,
short-term and B, long-term HbA1c
response prediction, respectively. The
colour bar indicates the weightage
assigned by elastic net to discriminate
between responders and non-responders.
Higher intensity in the colormap indicates
variables that are more robustly
informative (selected more consistently
across different iterations of model
training). ACR, albumin-to-creatinine
ratio; AU, acarbose use; BMI, body mass
index; CV, history of cardiovascular
disease; DMD, type 2 diabetes melitus
duration (≥2 years); DPP-4, dipeptidyl-
peptidase-4-inhibitors use; eGFR,
estimated glomerular filtration rate, GLD,
other oral glucose-lowering drugs use;
HbA1c, glycated haemoglobin; HDL, HDL
cholesterol; MA, micro/macro-
albuminuria; MU, metformin use; ML,
malignancy; PSC, psychological
conditions PV, peripheral vascular
disease; SBP, systolic blood pressure; TC,
total cholesterol; TG, triglycerides; LDL,
LDL cholesterol; SM, smoking status; SU,
sulphonylurea use; TZD, thiazolidines use
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short. The patients had a mean age of 66 years, 54% were women,
and 86% had a diabetes duration of ≥2 years (Table 1).
3.1 | HbA1c response prediction
The elastic net regularization-based generalized linear model identi-
fied short- and long-term HbA1c responders with an AUC = 0.80
(95% CI 0.78–0.83) and 0.81 (95% CI 0.79–0.84), sensitivity = 0.81
(95% CI 0.75–0.86) and 0.81 (95% CI 0.76–0.88), specificity = 0.67
(95% CI 0.61–0.78) and 0.65 (95% CI 0.60–0.78), respectively (see
File S1 for additional metrics). The performance of the generalized lin-
ear model outperformed the other two machine-learning algorithms
(support vector machine: AUC = 0.75 [95% CI 0.71–0.78] and 0.77
[95% CI 0.73–0.79] and random forests: AUC = 0.76 [95% CI
0.68–0.78] and 0.79 [95% CI 0.69–0.81]) in predicting short-term and
long-term responses, respectively. Using baseline HbA1c alone, we
obtained an AUC = 0.71 (95% CI 0.65–0.73) and 0.72 (95% CI
0.66–0.75) for predicting short- and long-term response, respectively.
3.2 | Important predictive variables
Different variables identified by the elastic net regularization to predict
short-term and long-term responders are shown in Figure 3. The following
variables were selected as important for short-term prediction (reported
as K1188 ×100 %, where K= total number of times a given variable was
selected in different iterations): baseline HbA1c (100%); thiazolidine
use (100%); eGFR (99.7%); and HDL cholesterol (98.3%). For long-
term outcome prediction, baseline HbA1c (100%), smoking status
(98.9%) and eGFR (86.5%) were selected as important predictors.
3.3 | Subgroups of distinct HbA1c responders
Figure 4 shows the mean trajectory (with 95% CI) of HbA1c values
over 24 months after insulin treatment initiation for each subgroup
with different short- and long-term HbA1c responses predicted by
the elastic net regularization-based generalized linear model. At
baseline, age, HbA1c level, total cholesterol, SBP, eGFR and smoking
status were significantly different among the four groups (Table 1).
Group 1 (short- and long-term responders), which included 558 (47%)
of the 1188 patients, had relatively high HbA1c at baseline when
compared to the other groups. Patients in this group responded sub-
stantially to the insulin treatment within 6 months and maintained suffi-
cient response until 24 months. Group 2 (short-term responders),
which included 36 patients (3%), was younger, with relatively low initial
HbA1c, low total cholesterol, low SBP, and high eGFR levels and more
smokers at baseline. Patients in this group responded sufficiently to
insulin treatment within 6 months but did not show sufficient response
(Δ HbA1c < 5 mmol/mol) after 6 months. Group 3 (no change in
response) included 558 (47%) patients and had the lowest HbA1c levels
at baseline. Patients in this subgroup did not show a sufficient decrease
in HbA1c throughout the 24 months of insulin treatment. Group
4 (long-term responders), which included 36 (3.8%) patients, was older,
with higher total cholesterol, higher SBP, and lower eGFR levels com-
pared with the other groups. After insulin treatment initiation, patients
in this group did not show a sufficient initial decrease in HbA1c but
showed better response after 6 months.
4 | DISCUSSION
We developed a novel supervised machine-learning framework to
predict short-term and long-term HbA1c response in patients with
T2DM after insulin treatment initiation using multiple demographic
and baseline clinical variables. The proposed system based on an elas-
tic net regularization-based generalized linear model correctly classi-
fied short- and long-term insulin treatment responders with good
performance (AUC ≥0.80). Baseline HbA1c, eGFR, smoking and use of
specific oral glucose-regulating drugs were identified as the most
important factors. In addition, subgroups with different predicted
short- and long-term responses differed in age, baseline HbA1c,
eGFR, total cholesterol and SBP levels.
Several previous studies have looked at variables for predicting
HbA1c response in patients with T2DM initiating metformin or
F IGURE 4 Comparison of glycated
haemoglobin (HbA1c; mmol/Mol) levels
in four groups against time predicted by
the elastic net regularization-based
generalized linear model. The graph
shows mean values with 95% confidence
interval. The time axis is divided into
6-month intervals. Here group 1, short-
and long-term responders; group
2, short-term responders; group 3, no
change in response; group 4, long-term
responders. To obtain distinct subgroups
of patients, we obtained a median
probability outputs of the generalized
linear model. HbA1c, glycated
haemoglobin
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sulphonylurea derivatives (detailed analysis and description of these
studies can be found in the review article by Martono et al13). In these
studies, baseline HbA1c, age, BMI and duration of diabetes were
found to be important predictors of HbA1c response. Consistent with
these findings, the present study showed that baseline HbA1c is impor-
tant for predicting both short- and long-term HbA1c response after
insulin initiation. We identified a substantial group of patients who
already had relatively low HbA1c levels at insulin initiation which
remained stable over time. Although these patients did not reach target
HbA1c levels and did not show sufficient response as defined in the
present study, they seem relatively well treated. It is possible that these
patients switched to insulin to reduce the adverse effects of oral treat-
ment. We also identified a substantial group of patients with elevated
HbA1c levels at baseline who responded rapidly to the treatment and
remained stable during the course of the treatment. We observed that
smoking status had a significant effect on the prediction performance
of the long-term HbA1c response. The small group of younger patients
with sufficient short-term response without further long-term improve-
ments included a higher percentage of smokers. It might be that
smoking status is a proxy for being less adherent to treatment,28,29 but
it can also be associated with insulin resistance.30 Finally, the use of
thiazolidines or repaglinide at baseline was predictive of short-term
response. These were mostly used by patients in the smaller group of
older patients which showed poor short-term but a good long-term
response. It is likely that these patients had switched from thiazolidines
or repaglinide to insulin, and may have been on too-low insulin dosing
schemes in the first months of treatment. It could also be that use of
these drugs is a proxy for clinical complexity.
Prior studies conducted in the Netherlands17,18 have looked at identi-
fying distinct trajectories of HbA1c response over time after insulin treat-
ment initiation using an unsupervised latent class growth modelling
algorithm.31 A study by Mast et al17 identified four different subgroups
on a database obtained from a centrally organized care system. The
majority of patients (89%) had stable HbA1c trajectories over time after
insulin treatment initiation. This group was similar in age and baseline
HbA1c levels to group 3 in the present study, showing stable HbA1c
levels. A recent study by Sidorenkov et al,18 using the same GIANTT data
as used in the present study, identified three distinct subgroups, where
the majority of patients (84%) showed a short-term response followed by
stable HbA1c trajectories. This group was also similar in age and baseline
HbA1c levels to group 3 in the present study.
To the best of our knowledge, this is the first study using a super-
vised machine-learning technique to predict short- and long-term
HbA1c response in patients with T2DM based on a clinical outcome
definition. The proposed supervised machine-learning framework may
lead to clinical tools which provide a probability estimate of patient
response to insulin treatment at baseline (before initiation) using clini-
cal data available from the medical record. It is important to note that
the model does not assume causality. The clinical utility of the pro-
posed method is multifold. It provides clinicians with the ability to
integrate multiple variables to predict both short-term and long-term
HbA1c response. Identifying patients who are likely to respond to
insulin only in the long term may assist clinicians to monitor and
uptitrate insulin dosage earlier in these patients. Similarly, identifying
patients who are likely to respond only in the short term may require
closer monitoring of patient adherence as well as the need for
uptitration. This provides the first step towards a more personalized
treatment where insulin treatment decisions are supported by
machine-learning algorithms based on individual patient predictors. A
clinician can integrate such clinical data-based predictions with addi-
tional information about patient preferences or risks for adverse
events when making decisions about insulin initiation.
Despite promising results (AUC ≥0.8), the present HbA1c
response prediction system is not yet ready for clinical use. A strength
of the present study is the use of LOSO cross-validation (mimicking a
real clinical scenario) to develop the proposed patient response pre-
diction system and subgroup identification. This provides a nearly
unbiased estimate of the generalization error on new patient testing
data. Several limitations need to be addressed in future work before
deployment of the HbA1c response prediction system. First, the
majority of patients in the present study were of western European
ethnicity (2% non-Europeans) and the results might not be generaliz-
able to the general population. Second, we look at HbA1c response
after insulin initiation using observational data, while the response
may be attributable to other factors, such as insulin dosing and regi-
men, other medication changes, medication adherence, and lifestyle
(eg, physical activity and diet). We had no data available to report on
these factors. Third, we developed two separate models for short-
and long-term prediction because of the limited dataset. A substantial
number of patients in the GIANTT database were excluded from the
analyses because they had insufficient follow-up or lacked an HbA1c
measurement before insulin initiation. This is a consequence of using
medical record data from a dynamic cohort. This can have an impact
on prediction performance, although it is difficult to say to what
extent. Validation of the proposed model on another dataset is there-
fore necessary to confirm the findings. In the future, we plan to
develop a single multi-label machine-learning model using a large
dataset from several sources. This should also include more recent
data, because the use of newer agents, such as glucagon-like peptide-
1 receptor agonists in combination with insulin may have increased.
For now, our results provide important proof-of-concept results to
guide future investigations leveraging the potential of machine learn-
ing in predicting drug response.
In conclusion, we show that a supervised machine-learning algo-
rithm performed well in predicting short- and long-term HbA1c
response after insulin initiation in patients with T2DM. This provides
the first step towards guided personalized treatment where insulin
treatment decisions are supported by machine-learning-based predic-
tions using individual patient clinical variables.
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